Artwork

Content provided by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A Game-Changing Cancer Drug Gives Stage 4 Breast Cancer Patients New Hope

14:01
 
Share
 

Manage episode 345344575 series 3409298
Content provided by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

For nearly half of all breast cancer patients – those with low levels of the HER2 protein – targeted treatment options have always been limited. Palliative chemo has been the standard of care in stage 4 metastatic patients – until now. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Shanu Modi, the lead researcher of a groundbreaking MSK trial that proved a drug that combines an antibody with a chemotherapy – trastuzumab deruxtecan (T-DXd) – can control cancer cells and extend survival in stage 4 HER2-low breast cancer patients. With a fresh FDA approval, T-DXd is now being tested on other cancers and changing the way oncologists treat their patients.

See omnystudio.com/listener for privacy information.

  continue reading

57 episodes

Artwork
iconShare
 
Manage episode 345344575 series 3409298
Content provided by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jonathon Musgrave and Memorial Sloan Kettering Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

For nearly half of all breast cancer patients – those with low levels of the HER2 protein – targeted treatment options have always been limited. Palliative chemo has been the standard of care in stage 4 metastatic patients – until now. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Shanu Modi, the lead researcher of a groundbreaking MSK trial that proved a drug that combines an antibody with a chemotherapy – trastuzumab deruxtecan (T-DXd) – can control cancer cells and extend survival in stage 4 HER2-low breast cancer patients. With a fresh FDA approval, T-DXd is now being tested on other cancers and changing the way oncologists treat their patients.

See omnystudio.com/listener for privacy information.

  continue reading

57 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide